We provide innovative analytical and bioanalytical solutions with quality data and fast turnaround time

About us

Founded in 2012, NovaBioAssays LLC is a Greater Boston-based contract research organization (CRO) specializing on innovative and on-demand analytical and bioanalytical solutions to meet the needs of our client's drug discovery and development. We assembled a team with established experience and expertise in both small molecule and protein bioanalytical science in biopharmaceutical industry, including experts from Pfizer, BMS etc. NovaBioAssays LLC has expanded to a full occupancy of a two-story laboratory building, equipped with state-of-the-art instrumentation to support growing demand from our clients. Our satisfied customers include top 20 biopharma companies, biotech and academic groups across the country and internationally. Our featured capacities can support various therapeutic modalities including protein/antibody/ADC, Oligonucleotides, small molecules and gene therapy.

Our Team

  • Dr. Chengjie Ji

    PhD in Analytical Chemistry

    Dr. Chengjie Ji is the founder and president of NovaBioAssays. Dr. Ji received his PhD in Analytical Chemistry at the University of Alberta in 2005. Dr. Ji worked in the Department of Pharmacokinetics, Dynamics & Metabolism at Pfizer from 2006 to 2012, where he developed and implemented many innovative UPLC-MRM MS assays for quantitative measurement of small and large molecule drugs/biomarkers in various biological matrices. He has published over a dozen research papers in renowned journals. In August 2012, he founded NovaBioAssays LLC. Since then, he has successfully built business relationships with many of the top 20 pharmaceutical and biotech companies in USA. For the past 8 years, his dedicated work allowed him to create a variety of enzyme columns and tools to enhance HDX workflow automation which are now available to scientists in the HDX-MS area. This allowed NovaBioAssays to become a pioneer HDX-MS service provider to patent law firms, pharmaceutical and biotech companies.

  • Dr. John Chen

    PhD in Analytical Chemistry

    As Senior Vice President, Dr. John Chen leads operations for the company's Bioanalytical Services. Prior to joining NovaBioAssays in 2016, he held scientific and management roles in Agilux Laboratories (now Charles River Laboratories), Synta Pharmaceuticals, NeoGenesis (now Merck), and Celgene (now BMS). With over 20 years of pharmaceutical and biotech industry experience in Bioanalysis and DMPK to support drug discovery and development, Dr. Chen's current research includes bioanalytical method development and validation using LC-MS and ligand binding assays, as well as quantitation and characterization of small molecules, oligonucleotides, peptides, and proteins. Dr. Chen earned a Ph.D. degree in Food Chemistry from Rutgers University in USA. He received a MS degree in Analytical Chemistry and BS degree in Chemistry from Peking University in China.


  • Dr. Jun Dai

    PhD in Analytical Chemistry

    Dr. Jun Dai is Vice President of Analytical Sciences at NovaBioAssays. Dr. Dai obtained her Ph.D. in Analytical Chemistry from University of Minnesota. Prior to joining NovaBioAssays, Dr. Dai worked for over fourteen years at Bristol-Myers Squibb Research and Development at Princeton New Jersey, where she built her biopharmaceutical expertise with a proven track record by leading many analytical projects and coordinating cross-functional team efforts. She has worked extensively in biologics characterization, complex chiral/achiral separations and purification, as well as biomarker method development to support the Discovery and Development of evolving drug modalities. Dr. Dai has published over twenty-five peer-reviewed papers and a book chapter. She also innovated the direct online capillary isoelectric focusing - mass spectrometry at both intact and subunit levels for complex protein therapeutics. At NovaBioAssays, Dr Dai continues her passion to provide innovative separation focused methodologies and strategies for clients to meet the analytical challenges of therapeutic molecules from early developability assessment to IND/BLA filing.